ETNB - 89bio Inc

14.84
0   0%

Share volume: 55,645,393
Last Updated: 10-29-2025
Pharmaceutical Products/Pharmaceutical Preparations: 3.16%

PREVIOUS CLOSE
CHG
CHG%
$14.84
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
23%
Profitability 25%
Dept financing 25%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0.27%
3 Months
69.21%
6 Months
82.98%
1 Year
47.66%
2 Year
103.85%
Key data
Stock price
$14.84
P/E Ratio 
0.00
DAY RANGE
$14.82 - $14.87
EPS 
-$3.46
52 WEEK RANGE
$4.16 - $15.06
52 WEEK CHANGE
$63.98
MARKET CAP 
1.061 B
YIELD 
N/A
SHARES OUTSTANDING 
145.984 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
1.36
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
$7,409,055
Company detail
CEO: Rohan Palekar
Region: US
Website: 89bio.com
Employees: 40
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

89bio, Inc. focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21.

Recent news